NEW YORK (GenomeWeb) — Singapore-based Clearbridge Health announced today that it has signed an agreement to promote Genome.One's GoExplore personalized genomics service to its customers in certain Asian markets.
Under the terms of the deal, Clearbridge clinicians will refer their patients in Singapore and Hong Kong to GoExplore, which sequences and analyzes an individual's DNA to assess his or her risk of developing 52 hereditary conditions, including cancers and heart diseases, as well as other conditions where monitoring or intervention can be beneficial. GoExplore is also designed to determine a person's likely response to more than 220 different types of medication.
Financial terms of the agreement were not disclosed.
"We are thrilled to be able to make clinically accredited genomic testing and analysis more widely available to people outside Australia through our partnership with Clearbridge," Genome.One CSO Marcel Dinger said in a statement.
Sydney-based Genome.One is a subsidiary of the Garvan Institute of Medical Research. About a year ago, it partnered with OneOme to offer genetic risk and pharmacogenomics testing to customers in Australia. Around that same time, Genome.One also launched a whole-genome sequencing service for healthy individuals called GoNavigate.